Identification of a novel orally bioavailable ERK5 inhibitor with selectivity over p38 alpha and BRD4.
Myers, S.M., Miller, D.C., Molyneux, L., Arasta, M., Bawn, R.H., Blackburn, T.J., Cook, S.J., Edwards, N., Endicott, J.A., Golding, B.T., Griffin, R.J., Hammonds, T., Hardcastle, I.R., Harnor, S.J., Heptinstall, A.B., Lochhead, P.A., Martin, M.P., Martin, N.C., Newell, D.R., Owen, P.J., Pang, L.C., Reuillon, T., Rigoreau, L.J.M., Thomas, H.D., Tucker, J.A., Wang, L.Z., Wong, A.C., Noble, M.E.M., Wedge, S.R., Cano, C.
Eur.J.Med.Chem.
